Format

Send to

Choose Destination
See comment in PubMed Commons below
J Atten Disord. 2008 Nov;12(3):248-53. doi: 10.1177/1087054708316250. Epub 2008 Apr 30.

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

Author information

1
New York University, School of Medicine, New York, NY 10016, USA. lenard.adler@med.nyu.edu

Abstract

OBJECTIVE:

Previously, data from 97 weeks of open-label atomoxetine treatment of adults with attention-deficit/hyperactivity disorder (ADHD) were reported. This final report of that study presents results from over 4 years of treatment.

METHOD:

Results were derived from the study of 384 patients (125 patients remaining in the open-label trial since the interim report), receiving up to 221 weeks of treatment. Primary efficacy measure was the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom score. Adverse events and vital signs were assessed.

RESULTS:

CAARS-Inv:SV Total ADHD Symptom scores decreased 30.2% (p < .001) during treatment. Similar, significant decreases were noted for the secondary efficacy measures, including the Sheehan Disability Scale Total score, which improved 25.3% (p < .001). Adverse events consisted primarily of pharmacologically (noradrenergic) expected effects.

CONCLUSIONS:

Results of this open-label study support the long-term efficacy, safety, and tolerability of atomoxetine for the treatment of adult ADHD.

PMID:
18448861
DOI:
10.1177/1087054708316250
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center